12th Sep 2016 06:17
LONDON (Alliance News) - Blue-chip drugmaker AstraZeneca PLC on Monday announced two new randomised phase 3b outcome trials for its Forxiga treatment, currently indicated for type-2 diabetes.
The two trials will be used to determine whether the drug can be used in treating chronic kidney disease and chronic heart failure in people without type-2 diabetes.
"Our transformative clinical research aims to address the multiple risk factors associated with cardiovascular morbidity and mortality, including diabetes, chronic heart failure and chronic kidney disease. By following the science, we are seeking to improve outcomes for millions of patients with cardiovascular disease around the world," said Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca